Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 11, Issue 3, pp 203–209 | Cite as

Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention

  • Carey Kimmelstiel
  • Robert Phang
  • Asif Rehman
  • William Rand
  • Regina Miele
  • Joanne Rhofiry
  • Debra A. MacIsaac
  • William Gouveia
  • Donna Denier
  • Richard C. Becker
Article

Abstract

Background:Platelet glycoprotein (GP) IIb/IIIa antagonists reduce the occurrence of death, myocardial infarction (MI) and urgent revascularization among patients undergoing percutaneous coronary intervention (PCI). Despite a similar mechanism of platelet inhibition, the three currently approved agents vary widely in cost.

Purpose: The purpose of this prospectively designed, retrospective analysis was to determine clinical outcomes for patients receiving abciximab, tirofiban or eptifibatide as adjunctive therapy during PCI at a single center. We hypothesized that there would be no difference in outcomes during hospitalization following PCI in patients receiving tirofiban or eptifibatide compared with those patients who received abciximab. Outcomes examined included in-hospital mortality, hemorrhagic procedural complications, need for recatheterization, peak creatine kinase following intervention and length of hospital stay (LOS).

Results: Two hundred and sixty seven consecutive patients in whom GP IIb/IIIa antagonist therapy was initiated in the catheterization laboratory for PCI were analyzed. Abciximab-treated patients were more likely to be undergoing primary (p<0.001) and rescue (p=0.022) PCI and to have received fibrinolytic therapy (p=0.013) when compared to patients receiving tirofiban or eptifibatide. There were no significant differences between abciximab- and non abciximab-treated patients in either the primary PCI or non primary PCI groups in any of the studied endpoints. In patients undergoing primary PCI, abciximab-treated patients when compared with non abciximab-treated patients exhibited a trend toward an increase in hospital LOS (7.8±7.0 d vs 6.2±3.9, p=0.19) and in the frequency of hemmorhagic complications (22.1% vs 5.3%, p=0.11). In patients not receiving fibrinolytic therapy, abciximab-treated patients experienced a trend toward increased hemmorhagic complications following PCI when compared to non abciximab-treated patients (10.2% vs 6.0%, p=0.28). Complications distant from the vascular access site comprised 62.5% of hemmorhagic complications in the abciximab-treated group, but only 20% of the complications in the non-abciximab treated population (p<0.001). These data suggest no differences in acute outcomes between groups of patients receiving abciximab or other approved GP IIb/IIIa antagonists highlighting a potential significant cost saving. These data will require interpretation following the publication of comparative trials.

GP IIb/IIIa antagonists coronary intervention complications 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961.Google Scholar
  2. 2.
    EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.Google Scholar
  3. 3.
    Impact Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422–1428.Google Scholar
  4. 4.
    RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445–1453.Google Scholar
  5. 5.
    Jafary FH, Kimmelstiel CD. Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors. J Thromb Thrombolysis 2000;9:163–174.CrossRefPubMedGoogle Scholar
  6. 6.
    PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.Google Scholar
  7. 7.
    Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407–1414.PubMedGoogle Scholar
  8. 8.
    Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103–1115.CrossRefPubMedGoogle Scholar
  9. 9.
    Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227–231.CrossRefPubMedGoogle Scholar
  10. 10.
    EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.Google Scholar
  11. 11.
    Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/ IIIa integrin blockade. Circulation 1998;98:2629–2635.PubMedGoogle Scholar
  12. 12.
    Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802–1820.PubMedGoogle Scholar
  13. 13.
    Neumann F-J, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695–2701.PubMedGoogle Scholar
  14. 14.
    PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339: 436–443.Google Scholar
  15. 15.
    Topol E. Do tirofiban and reopro give similar efficacy outcomes trial (TARGET). Oral presentation Annual Scientific Sessions, American Heart Association, New Orleans, Louisiana 2000.Google Scholar
  16. 16.
    Tcheng JE, Madan M, Cohen EA, et al. Enhanced suppression of the platelet receptor using integrilin (eptifibatide) therapy, American College of Cardiology Annual Scientific Session, Anaheim, CA, March, 2000.Google Scholar
  17. 17.
    Mark DB, Simons TA. Use of abciximab: Comparative economic data. Am Heart J 1999;137:S123–S125.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Carey Kimmelstiel
    • 1
  • Robert Phang
    • 1
  • Asif Rehman
    • 1
  • William Rand
    • 1
  • Regina Miele
    • 1
  • Joanne Rhofiry
    • 1
  • Debra A. MacIsaac
    • 1
  • William Gouveia
    • 1
  • Donna Denier
    • 1
  • Richard C. Becker
    • 1
  1. 1.Cardiac Catheterization LaboratoryThe New England Medical CenterBostonUSA

Personalised recommendations